oleclumab,ceralasertib,durvalumab,olaparib,danvatirsen,trastuzumab deruxtecan,cediranib,vistusertib
merck,astrazeneca,daiichi sankyo
['hudson']
hudson #aacr23 shows seer data w/5y survival increasing: due to collab trials, understanding cancer pathobiology... spectrum of late effects. shows illus from '14 review 
Business development, marketing and sales professional in the life sciences, cancer diagnostics, and genomics fields. Blog: https://t.co/IeMzCogxlt. Opinions are my own.